[Gynecomastia following cytotoxic treatment of testicular cancer].
A case of post-chemotherapy gynecomastia is reported in a 40 years old male patient with a tumor of seminomatous germinal cells with no evidence of tumoral reappearance or augmentation of the chorionic gonadotropin hormone. The existence of primary hypogonadism was tested. A differential diagnosis was performed and possible physiopathological mechanisms of the gynecomastia were analyzed in a patient previously treated for testicular cancer.
Sanz Ortiz
J
J
Secciones de Oncología Médica, Hospital Universitario Marqués de Valdecilla, Santander.
Amado Senarís
J A
JA
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects; D004407:Dysgerminoma / Q000188:drug therapy*; D006177:Gynecomastia / Q000139:chemically induced*; D006801:Humans; D008297:Male; D013736:Testicular Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D014747:Vinblastine / Q000009:adverse effects
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin
Ginecomastia después de tratamiento citotóxico en el cáncer de testículo.